Scarica l'app Stockscreener
156.39
0.08%
-0.12
Dopo l'orario di chiusura:
156.39
Precedente Chiudi:
$156.51
Aprire:
$157.24
Volume 24 ore:
520.94K
Relative Volume:
0.92
Capitalizzazione di mercato:
$8.59B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-52.83
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
-0.09%
1M Prestazione:
+6.86%
6M Prestazione:
+25.96%
1 anno Prestazione:
+74.99%
Intervallo 1D:
$153.68
$157.83
Intervallo di 1 settimana:
$142.71
$158.01
Portata 52W:
$83.90
$161.13
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
156.39 | 8.59B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Assenagon Asset Management S.A. Trims Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Personal Finance - Business Wire
Glaukos Shares Rise Amid Promising Trial Results - TipRanks
GKOS Stock Gains Following Positive Study Data on iDose Platform - MSN
(GKOS) Trading Signals - Stock Traders Daily
Glaukos reports sustained efficacy in iDose TR trials By Investing.com - Investing.com South Africa
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
Glaukos reports sustained efficacy in iDose TR trials - Investing.com
Glaukos Highlights Advances in Glaucoma Treatments - TipRanks
Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3 - TipRanks
Glaukos iDose TR Shows Strong 36-Month Results with 70% Patient Control Rate in Glaucoma Trial - StockTitan
Thomas Burns: The 2-Decade Bet That’s Paying Off - Orange County Business Journal
Here's Why You Should Add Glaukos Stock to Your Portfolio Now - MSN
Harbor Capital Advisors Inc. Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? - MSN
Glaukos stock soars to all-time high of $153.72 By Investing.com - Investing.com Nigeria
Glaukos (NYSE:GKOS) Hits New 1-Year HighStill a Buy? - MarketBeat
Glaukos stock soars to all-time high of $153.72 - Investing.com
(GKOS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Glaukos price target raised to $157 from $149 at BTIG - Yahoo Finance
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Benzinga
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Stifel backs Glaukos shares with higher price target and positive long-term iDose outlook - Investing.com Canada
Glaukos Corporation Sees A Bright Future In Huntsville - Huntsville Business Journal
Franklin Resources Inc. Purchases 6,948 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA - MSN
GKOS (Glaukos) Change In Working Capital : $-36.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
(GKOS)Analyzing Glaukos's Short Interest - Benzinga
(GKOS) Trading Report - Stock Traders Daily
Are Investors Undervaluing Glaukos Corporation (NYSE:GKOS) By 50%? - Simply Wall St
Glaukos (NYSE:GKOS) Reaches New 1-Year HighTime to Buy? - MarketBeat
Pharmaceutical giant chooses to invest $82 million in Huntsville facility - MSN
Glaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos president sells $498,715 in stock - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million By Investing.com - Investing.com Australia
Glaukos president sells $498,715 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):